Pretreatment clinical and hematological predictors of efficacy and immune-related adverse events in patients with advanced non-small cell lung cancer receiving first-line chemotherapy combined with immune checkpoint inhibitors

Abstract Background The combination of immune checkpoint inhibitors (ICI) and platinum-based chemotherapy has rapidly become the standard first-line treatment for advanced or metastatic non-small cell lung cancer (NSCLC). However, identifying reliable predictive factors of treatment response remains...

Description complète

Détails bibliographiques

Auteurs principaux:	Shun Matsuura, Kensuke Kita, Kyohei Matsushita, Takumi Nagasaki, Ryo Suzuki, Yuya Yamamoto, Kotaro Yamada, Ryuuichi Nakamura, Norimichi Akiyama, Kazuki Tanaka, Naoki Koshimizu
Format:	Artigo
Langue:	Inglês
Publié:	BMC 2026-02-01
Collection:	BMC Cancer
Sujets:	Advanced non-small cell lung carcinoma ECOG-PS Number of metastases Immune-related adverse events
Accès en ligne:	https://doi.org/10.1186/s12885-026-15733-9
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!